| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Phio Pharmaceuticals Corp.$1.02
-0.02 (-1.92%)
D 23Pipeline Score Overvalued Biotech · Commercial
Market Cap
12.66 M
EPS
-1.44
P/E Ratio
-
Value Trade
61.71 K
SEC Financials
Q1 2026Dilution Risk
40%R&D Expenses
2.79 M
Operating CF
-4.00 M
Total Assets
17.41 M
Total Liabilities
950.00 K
Equity
16.46 M
D/E Ratio
12,345
-0.91 %
Week
-12.1 %
1 Month
-5.22 %
3 Month
-9.92 %
6 Month
-99.52 %
5 Year
-100 %
All Time
Cash Data
Cash Position
17.03 M
Monthly Burn
1.33 M
Runway
10.9 mo
Burn Trend
SEC Filing
May 7, 2026
Overview
Volume
65.04 K
52 Week Range
0.81 - 4.19
% held by Insiders
10.71 %
% held by Institutions
5.75 %
Enterprise Value
-4.37 M
Total Shares
11.61 M
Short %
1.89 %
Float Shares
11.56 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Phio Pharmaceuticals Corp.
358Total events
2Upcoming
47Tier-1 (high impact)
2012 – 2026Coverage
Upcoming catalysts 2
Event history 356
Apr 15, 2026
◆Oral PresentationPresentation
Fireside chat with Force Family Office on Nobel Prize winning science takes on skin cancer
skin cancersource ↗
Q2 2026
◆FDA Feedback ReceivedPH-762FDA Meeting
FDA engagement regarding next-stage clinical development targeted for Q2 2026
cutaneous squamous cell carcinoma, melanoma, Merkel cell carcinomasource ↗
Mar 12, 2026
◆Oral PresentationPresentation
Phio Pharmaceuticals to present at Life Sciences Investor Forum
Jan 21, 2026
Sep 10, 2025
◆Oral PresentationPresentation
Phio Pharmaceuticals to present at H.C. Wainwright 27th Annual Global Investment Conference
Sep 3, 2025
▲Enrollment UpdatePH-762Trial
5th cohort patients now being treated in ongoing Phase 1b clinical trial
cutaneous squamous cell carcinoma, melanoma, Merkel cell carcinomasource ↗
Aug 14, 2025
◆Enrollment UpdatePH-762Trial
5th cohort enrolling patients in ongoing Phase 1b trial
cutaneous squamous cell carcinoma, melanoma, Merkel cell carcinomasource ↗
Aug 14, 2025
●Manufacturing MilestonePH-762CMC / Inspection
Entered into drug substance development services agreement with U.S. manufacturer
Jul 25, 2025
Jul 25, 2025
▲Manufacturing MilestonePH-762CMC / Inspection
Drug substance development services agreement with U.S. manufacturer for PH-762
cutaneous squamous cell carcinoma, Merkel cell carcinoma, melanomasource ↗
Drug Pipeline Intelligence
D23
Pipeline Score $2M
Pipeline ValueOvervalued
Valuation Signal2
Drugs Scored0.7x
rNPV / MCap Top 21%
Micro Cap (rank 721 of 911)
Percentile RankPhio Pharmaceuticals Corp. faces pipeline headwinds (23/100), with $263M risk-adjusted pipeline value, led by DP CD8 TIL in HNSCC (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DP CD8 TIL Monoclonal antibody | HNSCC | Phase 1 | NCT05902520 | 17% | $254M | ACTIVE NOT_RECRUITING | 18 | STALLED | C (45) | Dec 31, 2026 | - | LOW May 24, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
PH-762 | cutaneous squamous cell carcinoma, melanoma and Merkel cell carcinoma | Phase 1b | 2026-03-10 | In the Phase 1b trial of PH-762 for cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma, a pathological response rate of approximately 65% was observed across all dosing cohorts, with an 85% response rate (6 of 7 patients) in the highest-dose cohort. Read More | Phio Pharmaceuticals to Present at the Life Sciences Investor Forum on March 12, 2026 11 AM EDT Read More | |
PH-762 | cutaneous squamous cell carcinoma, melanoma and Merkel cell carcinoma | Phase 1b | 2026-03-10 | In the Phase 1b trial of PH-762 for cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma, a pathological response rate of approximately 65% was observed across all dosing cohorts, with an 85% response rate (6 of 7 patients) in the highest-dose cohort. Read More | Phio Pharmaceuticals to Present at the Life Sciences Investor Forum on March 12, 2026 11 AM EDT Read More | |
PH-762 | cutaneous squamous cell carcinoma, melanoma and Merkel cell carcinoma | Phase 1b | 2026-03-10 | In the Phase 1b trial of PH-762 for cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma, a pathological response rate of approximately 65% was observed across all dosing cohorts, with an 85% response rate (6 of 7 patients) in the highest-dose cohort. Read More | Phio Pharmaceuticals to Present at the Life Sciences Investor Forum on March 12, 2026 11 AM EDT Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in PHIO
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
PHIO Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
PHIO▼ -5.9%on this news
Phio Pharmaceuticals Announces “How siRNA Therapy can Change the Course of Cancer Treatment” in a Fireside Chat with Force Family Office on Monday, June 29, 2026
Phio Pharmaceuticals announced that CEO Robert Bitterman will participate in a fireside chat discussing siRNA therapy's potential in cancer treatment. The event, scheduled for June 29, 2026, will feature insights from Dr. Jim Cardia on the company's INTASYL® technology and its application in immuno-oncology. This highlights Phio's commitment to advancing cancer therapeutics.
Read more →PHIOPhio Pharmaceuticals Reaches Key Milestone in Advancing Lead Candidate PH-762
Phio Pharmaceuticals has announced the start of commercial-scale cGMP production of its lead candidate PH-762 at Nitto Denko Avecia. This milestone supports the upcoming clinical trial as the company progresses its intratumoral program. The recent completion of a Phase 1b dose-escalation study for PH-762 indicates promising developments in treating skin cancers.
Read more →PHIOPhio Pharmaceuticals Announces Participation in the Life Sciences Investor Forum on June 24-25, 2026
Phio Pharmaceuticals will participate in the Life Sciences Investor Forum on June 24-25, 2026. CEO Robert Bitterman will present the company's INTASYL siRNA platform, focusing on its lead candidate PH-762 for treating skin cancers. The event will feature a live Q&A session and one-on-one meetings for investors.
Read more →PHIOPhio Pharmaceuticals Announces “Innovations in Skin Cancer Treatment and Prevention” in a Fireside Chat with Force Family Office on Tuesday, May 19, 2026
Phio Pharmaceuticals will participate in a fireside chat on May 19, 2026, discussing innovations in skin cancer treatment. CEO Robert Bitterman and dermatologist Dr. Mary Spellman will highlight the company's INTASYL® gene silencing technology and its lead candidate PH-762, which is currently in a Phase 1b trial for skin cancers. The trial has reported positive pathological response rates.
Read more →PHIOPhio Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update
Phio Pharmaceuticals reported its Q1 2026 financial results, highlighting the successful completion of its Phase 1b clinical trial for PH-762, aimed at treating skin cancer. The company secured key development agreements and strengthened its financial position with approximately $23.7 million in net proceeds from equity financings. While the trial data is pending formal analysis, an FDA submission is anticipated in Q2 2026 to discuss next steps for PH-762.
Read more →PHIOPhio Pharmaceuticals Announces “Nobel Prize Winning Science Takes on Skin Cancer” in a Fireside Chat with Force Family Office on Wednesday, April 15, 2026
Phio Pharmaceuticals is hosting a virtual fireside chat on April 15, 2026, featuring CEO Robert Bitterman and Dr. R. Todd Plott from Epiphany Dermatology. They will discuss the company's INTASYL technology and its lead candidate, PH-762, which targets skin cancer. The Phase 1b trial results indicate a significant pathological response rate, with FDA engagement planned for the second quarter of 2026.
Read more →PHIOPhio Pharmaceuticals Announces “Nobel Prize Winning Science Takes on Skin Cancer” in a Fireside Chat with Force Family Office on Wednesday, April 15, 2026
Phio Pharmaceuticals is set to host a fireside chat titled 'Nobel Prize Winning Science Takes on Skin Cancer' with the Force Family Office on April 15, 2026. This event aims to discuss groundbreaking scientific advancements in the treatment of skin cancer. The involvement of Nobel Prize-winning science is expected to attract significant attention and interest from investors.
Read more →PHIOPhio Pharmaceuticals Announces Presentation at Centri Capital Conference on April 14, 2026
Phio Pharmaceuticals will present at the Centri Capital Conference on April 14, 2026. CEO Robert Bitterman will discuss the company's clinical advancements and the potential of its INTASYL technology in immuno-oncology. The event will take place at Nasdaq Marketsite in New York City, with a virtual attendance option available.
Read more →PHIOPhio Pharmaceuticals Announces Agreement with U.S. cGMP Manufacturing Source for Drug Product, PH-762
Phio Pharmaceuticals has announced a cGMP manufacturing agreement for its lead compound, PH-762, aimed at treating cutaneous carcinomas. The agreement will support clinical trials and commercial supply. In a Phase 1b trial, PH-762 demonstrated a 65% pathological response rate in patients, with no reported serious adverse events. The company plans to engage with the FDA in the second quarter of 2026.
Read more →PHIOPhio Pharmaceuticals Announces American Academy of Dermatology 2026 Presentation Featuring Clinical Study Results from Study of PH-762 for Cutaneous Carcinoma Underscoring Clinical Pipeline Advancement
Phio Pharmaceuticals announced a podium presentation at the American Academy of Dermatology on March 28, 2026, highlighting results from its Phase 1b clinical study of PH-762 for cutaneous carcinomas. The study demonstrated encouraging safety and efficacy results, with a significant pathological response rate. The company plans to engage with the FDA regarding further clinical development.
Read more →PHIO▲ +7.7%on this news
Phio Pharmaceuticals Announces “A Groundbreaking Approach to Treating Skin Cancer” in a Fireside Chat with Force Family Office
Phio Pharmaceuticals will participate in a fireside chat on March 18, 2026, to discuss its innovative INTASYL gene silencing technology for treating skin cancer. The company's lead candidate, PH-762, has shown promising results in a Phase 1b trial for cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma. Phio aims to engage with the FDA regarding further clinical development in the second quarter of 2026.
Read more →PHIOPhio Pharmaceuticals to Present at the Life Sciences Investor Forum on March 12, 2026 11 AM EDT
Phio Pharmaceuticals Corp. announced that its CEO, Robert Bitterman, will present at the Life Sciences Investor Forum on March 12, 2026, to discuss the company's INTASYL siRNA platform and update on the lead clinical candidate, PH-762. The Phase 1b trial for PH-762, aimed at treating various skin cancers, reports a 65% pathological response rate among patients. This presentation offers stakeholders a chance to interact directly with company management and ask questions.
Read more →PHIOPhio Pharmaceuticals Reports 2025 Year-End Financial Results and Business Update
Phio Pharmaceuticals reported its 2025 financial results, highlighting the completion of the Phase 1b trial for PH-762, which showed favorable safety and tolerability data. The company raised $23.7 million through financings, extending its cash runway into the first half of 2027. Future FDA submissions for PH-762 are planned for Q2 2026 as the company progresses with its clinical development.
Read more →PHIOPhio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
Phio Pharmaceuticals has announced its participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series. This initiative aims to connect the company with potential investors and stakeholders. The virtual format allows for broader participation and engagement, enhancing the company's visibility in the market.
Read more →PHIOPhio Pharmaceuticals Aligns Leadership Team to Support Next Stage Development of PH-762 and Advancement of PH-894
Phio Pharmaceuticals has announced key leadership appointments to strengthen its operational capabilities as it prepares for upcoming regulatory discussions and clinical milestones for its drug candidates PH-762 and PH-894. Lisa Carson has been promoted to CFO, while Jennifer Phillips and Kimberly Man have taken on significant roles in regulatory affairs and program development, respectively. These changes aim to enhance the company's readiness for the next stages of development.
Read more →PHIO▲ +24.4%on this news· ran to +83% by day 3
Phio Announces Safety Monitoring Committee’s (SMC) Positive Wrap-up on Lead Clinical Candidate PH-762 in Skin Cancer Trial
Phio Pharmaceuticals announced positive results from the Safety Monitoring Committee regarding its lead candidate PH-762 in a Phase 1b trial for skin cancer. The trial showed an 85% pathological response rate, with no serious adverse events reported. The company plans to submit an FDA proposal for next steps in clinical study design by Q2 2026.
Read more →PHIOPhio Pharmaceuticals Announces Participation in Third Annual DealFlow Discovery Conference
Phio Pharmaceuticals will present at the DealFlow Discovery Conference on January 28, 2026. CEO Robert Bitterman will discuss the company's INTASYL gene silencing technology and its ongoing Phase 1b trial for PH-762, targeting skin cancers. Investors can schedule one-on-one meetings with the management team during the event.
Read more →PHIO▼ -5.3%on this news
Phio Pharmaceuticals Announces Key Tumor Response Data from all Cohorts in Intratumoral PH-762 Dose Escalation Cutaneous Carcinoma Trial
Phio Pharmaceuticals announced promising results from its Phase 1b trial of PH-762, showing a 70% overall response rate in patients with cutaneous squamous cell carcinoma. Notably, 10 out of 14 responders achieved complete clearance. The treatment demonstrated favorable safety and tolerability across all dose levels, with no significant adverse effects reported.
Read more →PHIOPhio Pharmaceuticals Announces Participation in the Sidoti Micro-Cap Virtual Investor Conference January 21-22, 2026
Phio Pharmaceuticals has announced its participation in the Sidoti Micro-Cap Virtual Investor Conference scheduled for January 21-22, 2026. This event presents an opportunity for the company to connect with potential investors and enhance its visibility in the market. The participation reflects Phio's commitment to engaging with the investment community.
Read more →PHIO▼ -6.4%on this news
Phio Pharmaceuticals Announces Significant Step Forward in its Drug Development Program for PH-762
Phio Pharmaceuticals has announced a significant advancement in its drug development program for PH-762, with the FDA accepting its nonclinical protocol study design. A toxicology study is set to begin in Q1 2026, which is essential before initiating a human pivotal trial. The ongoing Phase 1b trial has shown promising safety and efficacy results for treating skin cancer.
Read more →PHIOPhio Pharmaceuticals Announces Completion of Enrollment in Phase 1b Clinical Trial of INTASYL siRNA Lead Compound PH-762
Phio Pharmaceuticals has completed enrollment in its Phase 1b clinical trial for PH-762, a siRNA compound targeting skin cancer. The trial evaluates the safety and tolerability of PH-762 in patients with various skin cancers. Initial results show promising pathologic responses, with no significant adverse effects reported. Further results are expected in Q1 2026.
Read more →PHIOPhio Pharmaceuticals Announces Upcoming Podium Presentation at the Advanced Therapies USA 2025 Congress
Phio Pharmaceuticals announced a podium presentation at the Advanced Therapies USA 2025 Congress, showcasing its INTASYL siRNA drug technology. The presentation will highlight the potential of PH-762, an INTASYL compound aimed at treating cutaneous carcinomas. CEO Robert Bitterman emphasized the technology's promise in enhancing cancer treatment and fulfilling medical needs.
Read more →PHIOPhio Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
Phio Pharmaceuticals reported positive results from its Phase 1b trial of PH-762, achieving significant tumor clearance in skin cancer patients. The company secured financing to extend its cash runway into 2027 and received a favorable safety review. However, the net loss for Q3 2025 increased compared to the previous year.
Read more →PHIO▲ +5.4%on this news
Phio Pharmaceuticals to Present Recent Clinical Results from Skin Cancer Trial with siRNA based INTASYL PH-762
Phio Pharmaceuticals will present clinical data from its Phase 1b trial of PH-762 at the SITC Annual Meeting. The trial evaluates the safety of PH-762, an siRNA therapy targeting skin cancers. The presentation will take place in National Harbor, Maryland from November 7-9, 2025.
Read more →PHIO▲ +5.4%on this newsshared move
Phio Pharmaceuticals Announces INTASYL PH-762 is Named Immunomodulatory Solution of the Year in the BioTech Breakthrough Award Program
Phio Pharmaceuticals has announced that its INTASYL compound PH-762 has won the 2025 Immunomodulatory Solution of the Year award from the BioTech Breakthrough Awards program. This recognition underscores the potential of PH-762 as a non-surgical treatment for cutaneous carcinomas. The award reflects Phio's commitment to advancing cancer therapies through innovative gene silencing technology.
Read more →PHIO▼ -9.3%on this news
Phio Pharmaceuticals Announces Exercise of Warrants for Approximately $13.4 Million Gross Proceeds
Phio Pharmaceuticals announced the exercise of warrants for approximately $13.4 million in gross proceeds. The warrants, originally issued between July 2024 and July 2025, will be exercised at various prices. The funds will primarily be used for working capital and to expedite the clinical development of PH-762, a treatment for skin cancers.
Read more →PHIO▼ -9.3%on this newsshared move
Phio Pharmaceuticals Announces Positive Pathology Results: Final Maximum Dose Cohort for INTASYL PH-762 Skin Cancer Trial
Phio Pharmaceuticals announced promising results from its Phase 1b trial of PH-762 for treating cutaneous squamous cell carcinoma. The trial reported 100% tumor clearance in one patient and significant responses in others. The Safety Monitoring Committee confirmed a favorable safety profile with no dose-limiting toxicities observed. These results suggest PH-762 may provide a viable non-surgical treatment option.
Read more →PHIOPhio Pharmaceuticals Announces Appointment of Mr. David H. Deming to the Position of Lead Independent Director
Phio Pharmaceuticals has appointed David H. Deming as Lead Independent Director. With over 30 years of experience in investment banking, including a significant tenure at JP Morgan, Deming's expertise is expected to benefit Phio as it develops its INTASYL gene silencing technology aimed at treating cancer. The company is currently conducting a Phase 1b trial for its lead compound, PH-762.
Read more →PHIOPhio Pharmaceuticals to Present at the Life Sciences Future Conference
Phio Pharmaceuticals will present updates on its Phase 1b clinical trial for PH-762 at the Life Sciences Future Conference on September 26, 2025. CEO Robert Bitterman will discuss the trial's progress and future strategies. The conference aims to connect key stakeholders in the Pennsylvania life sciences community.
Read more →PHIOPhio Pharmaceuticals to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Phio Pharmaceuticals is set to present at the H.C. Wainwright 27th Annual Global Investment Conference, discussing its ongoing Phase 1b clinical trial for skin cancer treatment with PH-762. CEO Robert Bitterman will provide updates on the trial and future strategies. The event will take place from September 8 to 10, 2025, in New York City.
Read more →PHIOPhio Pharmaceuticals to Present at the H.C. Wainwright 27 th Annual Global Investment Conference Clinical trial advances to anticipated final cohort for INSTASYL siRNA lead product candidate PH-762 5th cohort patients no
Phio Pharmaceuticals is progressing with its Phase 1b clinical trial for the siRNA product candidate PH-762, aimed at treating skin cancers. The company will present its findings at the H.C. Wainwright 27th Annual Global Investment Conference scheduled for September 8-10, 2025. CEO Robert Bitterman plans to discuss the development strategy for PH-762 as the trial approaches its final cohort. The treatment could potentially offer a non-surgical option for skin cancer patients. Forward-looking statements about the product's success and funding challenges highlight inherent risks in the ongoing clinical development.
Read more →PHIOPhio Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update
Phio Pharmaceuticals reported its Q2 2025 financial results and provided updates on its clinical trials. The ongoing Phase 1b trial for PH-762 has shown promising safety and efficacy results in treating various skin cancers. The company is now enrolling patients for the final cohort of the trial. Financially, Phio reported a net loss of $2.2 million for the quarter, reflecting increased research and administrative expenses.
Read more →PHIOPhio Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update Clinical trial advances for INSTASYL siRNA lead product candidate PH-762 5th cohort enrolling patients in on-going clinical
Phio Pharmaceuticals reported its financial results for Q2 2025, highlighting the continued enrollment of patients in the fifth cohort of its ongoing Phase 1b clinical trial for PH-762, targeting various skin cancers. The trial has shown encouraging pathologic responses in treated patients, with no significant adverse effects reported. However, the company also experienced a net loss of $2.2 million for the quarter, up from the previous year, indicating growing operational costs. Phio maintains a strong cash position of about $10.8 million, enabling it to continue its developmental efforts.
Read more →PHIOPhio Pharmaceuticals Announces Exercise of Warrants for Approximately $2.5 Million Gross Proceeds
Phio Pharmaceuticals Corp. has announced the exercise of certain warrants, generating approximately $2.5 million in gross proceeds. The warrants, originally issued in late 2024 and early 2025, will allow the purchase of shares at prices between $2.00 and $2.485. The funds are intended for working capital and corporate purposes, with the offering expected to close by July 28, 2025.
Read more →PHIO▲ +9.2%on this newsshared move
Phio Pharmaceuticals Announces Pathology Results for Four of Five Patients in Fourth Cohort
Phio Pharmaceuticals announced positive pathologic results from its Phase 1b trial for PH-762, with one patient achieving complete tumor clearance and another showing partial response. The trial, which includes patients with cutaneous squamous cell carcinoma and Merkel cell carcinoma, has not reported any dose-limiting toxicities. The company is now enrolling for the final cohort of the study.
Read more →PHIO▲ +9.2%on this newsshared move
Phio Pharmaceuticals Announces Agreement with U.S. Manufacturing Source for Drug Substance
Phio Pharmaceuticals has entered into a drug substance development agreement with a U.S. manufacturer for its lead compound, PH-762. This partnership aims to enhance the development of PH-762, which is currently being evaluated in a Phase 1b trial for treating cutaneous squamous cell carcinoma, Merkel cell carcinoma, and melanoma. The collaboration is seen as a significant step in advancing Phio's intratumoral program.
Read more →PHIO▲ +9.2%on this newsshared move
Phio Pharmaceuticals Announces Agreement with U.S. Manufacturing Source for Drug Substance -Agreement covers contract development and manufacturing of lead compound PH-762 King of Prussia, Pennsylvania-(Newsfile Corp.
Phio Pharmaceuticals has announced a comprehensive agreement with a U.S. manufacturer for the development and cGMP manufacture of its lead compound PH-762. This collaboration is aimed at advancing Phio's treatment program for cutaneous carcinomas. Currently, the company is enrolling patients for the final cohort in its Phase 1b dose escalation study targeting cutaneous squamous cell carcinoma, Merkel cell carcinoma, and melanoma. The partnership is considered a strategic advantage by the management team, signaling confidence in the manufacturing quality and expertise.
Read more →PHIO▲ +9.2%on this newsshared move
Phio Pharmaceuticals Announces Exercise of Warrants for Approximately $2.5 Million Gross Proceeds King of Prussia, Pennsylvania--(Newsfile Corp.
Phio Pharmaceuticals Corp. announced the exercise of outstanding warrants, generating gross proceeds of approximately $2.5 million. The exercise involves warrants for the purchase of up to 928,596 shares, with various exercise prices set between $2.00 and $2.485 per share. The funds will be utilized for general corporate purposes, enhancing the company's ability to advance its INTASYL gene silencing technology focused on immuno-oncology therapeutics. The offering is expected to close around July 28, 2025, subject to customary conditions.
Read more →PHIOPhio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Clinical Trial to Fifth Dose Escalation Cohort
Phio Pharmaceuticals announced that its Safety Monitoring Committee has recommended advancing the PH-762 clinical trial to the fifth dose escalation cohort. The fourth cohort demonstrated a supportive safety profile, with no serious adverse events reported. The trial is evaluating PH-762 for treating various skin cancers, and results from the fourth cohort are expected soon.
Read more →PHIOPhio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Clinical Trial to Fifth Dose Escalation Cohort -Phio's lead clinical siRNA compound PH-762 demonstr
Phio Pharmaceuticals has received a positive recommendation from the Safety Monitoring Committee to advance its PH-762 skin cancer clinical trial to the fifth dose escalation cohort. The trial has demonstrated a supportive safety profile, with no serious adverse events reported in the current cohort evaluated. Initial results from previous cohorts indicate promising efficacy, including complete tumor clearance in several patients. The company anticipates completing enrollment for the final cohort by Q3 2025.
Read more →PHIOPhio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
Phio Pharmaceuticals Corp. will participate in a virtual non-deal roadshow on June 30, 2025, where CEO Robert Bitterman will discuss the company's INTASYL gene silencing technology and its ongoing Phase 1b clinical trial for skin cancer treatment. The trial has reported positive interim safety and efficacy results for the lead compound PH-762. Stakeholders are invited to join the presentation and Q&A session.
Read more →PHIO▲ +20.3%on this news
Phio Pharmaceuticals Announces Strategic Initiative to Create Awareness of the Comprehensive INTASYL siRNA Portfolio
Phio Pharmaceuticals has launched a strategic initiative to enhance awareness of its INTASYL siRNA portfolio, which includes around 30 compounds. The company reported positive interim results from a Phase 1b trial of PH-762 for skin cancer treatment. New leadership appointments aim to focus on strategic business development and financial management.
Read more →PHIO▲ +20.3%on this newsshared move
Phio Pharmaceuticals Announces Strategic Initiative to Create Awareness of the Comprehensive INTASYL siRNA Portfolio - Robert Infarinato named VP, Strategic Development - Lisa Carson named as new VP, Finance and Administ
Phio Pharmaceuticals Corp. has announced a strategic initiative to enhance awareness of its INTASYL siRNA portfolio, which includes about 30 compounds. The company has reported positive interim trial results for its lead compound, PH-762, targeted at treating skin cancer. Robert Infarinato has been appointed as VP of Strategic Development, while Lisa Carson joins as VP of Finance and Administration, both expected to guide the company's strategic direction. However, Phio acknowledges several inherent risks that may affect its development and commercialization processes.
Read more →PHIOPhio Pharmaceuticals Announces Participation in the Sidoti Micro-Cap Virtual Investor Conference
Phio Pharmaceuticals announced its participation in the Sidoti Micro-Cap Virtual Investor Conference, scheduled for May 21-22, 2025. CEO Robert Bitterman will present updates on the company's INTASYL siRNA technology and ongoing clinical trials for skin cancer treatment. Investors can register for the presentation and one-on-one meetings with the CEO.
Read more →PHIOPhio Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
Phio Pharmaceuticals reported strong progress in its Phase 1b clinical trial for PH-762, with significant tumor clearance observed in patients with cutaneous squamous cell carcinoma. The company has raised sufficient capital to continue its clinical efforts and has received recognition for its innovative siRNA technology. No adverse effects have been reported, indicating a favorable safety profile.
Read more →PHIOPhio Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update Clinical trial advances for INSTASYL siRNA lead product candidate PH-762 4th Cohort enrolling and treating patients in on-goi
Phio Pharmaceuticals has announced its financial results for the first quarter of 2025, highlighting the ongoing Phase 1b clinical trial of its lead product candidate, PH-762. The trial is evaluating the efficacy of the drug in patients with cutaneous squamous cell carcinoma and other skin cancers, showing promising results in tumor clearance. The company has successfully raised additional capital and reported a reduction in research and development costs. However, the trial also noted some patients did not respond to treatment, and the company continues to incur financial losses.
Read more →PHIO▲ +18.6%on this news
Phio Pharmaceuticals Announces Positive Pathology Results in Third Cohort in INTASYL PH-762 Skin Cancer Clinical Trial
Phio Pharmaceuticals announced positive results from its Phase 1b clinical trial of PH-762 for cutaneous squamous cell carcinoma, with a complete pathologic response observed in 2 out of 3 patients in the third cohort. The trial, which has shown no significant adverse effects, aims to evaluate the safety and efficacy of this potential non-surgical treatment. Results will be presented at the Society for Investigative Dermatology Annual Meeting on May 10th.
Read more →PHIO▲ +18.6%on this newsshared move
Phio Pharmaceuticals Announces Positive Pathology Results in Third Cohort in INTASYL PH-762 Skin Cancer Clinical Trial - Complete Pathologic Response reported in 2 patients in the Third Cohort with cutaneous squamous cel
Phio Pharmaceuticals has announced promising results from its ongoing INTASYL PH-762 clinical trial for cutaneous squamous cell carcinoma. In the third cohort of the trial, 2 out of 3 patients achieved a complete pathologic response, indicating significant tumor clearance. The drug, PH-762, has shown a favorable safety profile with no reported dose-limiting toxicities. As the trial progresses, Phio expects to complete patient enrollment by Q3 2025, providing further insights into the efficacy and safety of this potential non-surgical treatment for skin cancer.
Read more →PHIO▲ +52.5%on this news· ran to +118% by day 3
Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Study to Fourth Dose Escalation Cohort
Phio Pharmaceuticals announced a positive recommendation from the Safety Monitoring Committee to escalate doses in its Phase 1b trial for PH-762, a siRNA compound targeting skin cancer. The third cohort showed a supportive safety profile with no serious adverse events. Previous cohorts demonstrated promising efficacy, with complete tumor clearance in some patients. The trial aims to establish PH-762 as a viable non-surgical treatment option.
Read more →PHIO▲ +52.5%on this news· ran to +118% by day 3shared move
Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Study to Fourth Dose Escalation Cohort -Phio's lead clinical siRNA compound PH-762 demonstrates sup
Phio Pharmaceuticals has received a positive recommendation from the Safety Monitoring Committee to advance its Phase 1b clinical trial of PH-762 for skin cancer to the fourth dose escalation cohort. The clinical trial has shown that PH-762 has a supportive safety profile, with no serious adverse events observed in the third cohort of patients. Previous cohorts demonstrated promising results, including complete tumor clearance in some patients. The trial aims to assess PH-762's effectiveness as a non-surgical treatment alternative for cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma.
Read more →PHIOPhio Pharmaceuticals Announces Podium Presentations on INTASYL siRNA Lead Product Candidates PH-762 and PH-894
Phio Pharmaceuticals announced podium presentations for its lead INTASYL siRNA candidates, PH-762 and PH-894, at the ITOC Conference in Munich. PH-762 targets PD-1 and is in an ongoing clinical trial for skin cancers, while PH-894 enhances NK cell activity for adoptive cell therapy. These developments underscore Phio's commitment to advancing cancer immunotherapy.
Read more →PHIOPhio Pharmaceuticals Reports 2024 Year End Financial Results and Provides Business Update
Phio Pharmaceuticals reported its financial results for 2024 and provided updates on its clinical trial for PH-762, an siRNA candidate for skin cancers. The ongoing Phase 1b trial has shown promising tumor response rates and has been well tolerated among patients. The company has raised approximately $9.2 million to support its clinical efforts and is transitioning towards a product development focus.
Read more →PHIOPhio Pharmaceuticals Reports 2024 Year End Financial Results and Provides Business Update Continues advancing clinical trial for INSTASYL siRNA lead product candidate PH-762 3 rd Cohort now fully enrolled in on-going cli
Phio Pharmaceuticals reported its financial results for 2024, highlighting advancements in its PH-762 clinical trial for cancer treatment. The trial is progressing with the third cohort fully enrolled and early results indicating effective tumor responses. Financial measures have been implemented, including capital raising and cost rationalization, leading to a reduced net loss. The company aims to focus on product development and has emphasized the potential of its INTASYL siRNA technology.
Read more →PHIOAmerican Academy of Dermatology Awards Podium Presentation to Phio Pharmaceutical’s Clinical Research at 2025 Annual Meeting
Phio Pharmaceuticals presented interim results from its Phase 1b study of PH-762 at the American Academy of Dermatology's annual meeting. The study focuses on treating cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma. Notably, two out of four patients in the second dose cohort achieved a complete response. The company plans to initiate screening for the fourth dose cohort in early April.
Read more →PHIO▲ +5.3%on this newsshared move
Phio Pharmaceuticals Announces Completion of Enrollment in Third Safety Cohort in PH-762 Phase 1b Dose-Escalation Study
Phio Pharmaceuticals has announced the completion of enrollment for the third safety cohort in its Phase 1b dose-escalation study of PH-762, aimed at treating skin cancers. The study evaluates the safety and tolerability of PH-762, which utilizes INTASYL siRNA technology. The company plans to begin screening for the fourth dose cohort in early April.
Read more →PHIOPhio Pharmaceuticals Announces Appointment of David H. Deming to Board of Directors
Phio Pharmaceuticals has announced the appointment of David H. Deming to its Board of Directors, effective February 19, 2025. Mr. Deming, who has over 30 years of experience in investment banking, will contribute his expertise to the board, particularly on the Nominating Committee. This strategic addition is expected to aid Phio in advancing its mission to develop innovative gene silencing therapeutics aimed at enhancing immune cell efficacy in cancer treatment.
Read more →PHIO▼ -7.7%on this news· ran to -19% by day 3
Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
Phio Pharmaceuticals will participate in the Renmark Financial Communications Virtual Non-Deal Roadshow on January 29, 2025. CEO Robert Bitterman will present the company's INTASYL siRNA technology and provide updates on the clinical trial for PH-762, a treatment for skin cancers. The event aims to engage stakeholders and investors.
Read more →PHIOPhio Pharmaceuticals Announces Closing of $1.83 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Phio Pharmaceuticals has successfully closed a registered direct offering, raising $1.83 million to support its clinical activities, particularly for the Phase 1b trial of its lead product candidate, PH-762. The funds will also aid in advancing another candidate, PH-894. This financing marks a significant step in the company's development strategy.
Read more →PHIO▲ +9.4%on this newsshared move
Phio Pharmaceuticals Announces $1.83 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Phio Pharmaceuticals Corp. has announced a registered direct offering, raising $1.83 million by issuing 610,000 shares of common stock at $3.00 per share. Additionally, a concurrent private placement will feature short-term unregistered warrants for an additional 1,220,000 shares. These proceeds are intended for working capital and general corporate purposes. The offering is scheduled to close on or about January 17, 2025, pending customary conditions.
Read more →PHIO▼ -25.7%on this newsshared move
Phio Pharmaceuticals Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Phio Pharmaceuticals Corp. has announced a registered direct offering of $2.5 million, selling 833,335 shares of common stock at $3.00 each. In addition, the company will issue warrants in a concurrent private placement, potentially raising additional capital. The proceeds from the offering are intended for working capital and other corporate purposes. The offering follows Nasdaq rules and is set to close around January 15, 2025, pending customary conditions. This initiative is part of Phio's strategy to enhance its clinical-stage biotechnology endeavors using its INTASYL siRNA technology aimed at improving cancer treatments.
Read more →PHIO▼ -45.8%on this news· ran to -60% by day 1shared move
Phio Pharmaceuticals Announces $3.19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Phio Pharmaceuticals Corp. has announced a registered direct offering of approximately $3.19 million, selling 1,063,670 shares of common stock at $3.00 per share. This offering, structured according to Nasdaq rules, is expected to close on January 15, 2025, subject to customary conditions. Alongside, the company will issue unregistered short-term warrants for additional shares, aimed at enhancing its financial position for general corporate needs and working capital.
Read more →PHIO▲ +290.5%on this newsshared move
Phio Pharmaceuticals Announces Promising Results of Second Cohort from Its Ongoing Clinical Study of PH-762
Phio Pharmaceuticals announced promising results from the second cohort of its Phase 1b clinical study of PH-762, with two patients achieving complete tumor clearance in cutaneous squamous cell carcinoma. The study, which evaluates the safety and tolerability of PH-762, reported no significant adverse events. The company is optimistic about further enrollment and higher dose assessments.
Read more →PHIO▲ +290.5%on this newsshared move
Phio Pharmaceuticals Announces Promising Results of Second Cohort from its Ongoing Clinical Study of PH-762 Pathologic Complete Response reported for 2 patients with cutaneous Squamous Cell Carcinoma
Phio Pharmaceuticals has reported promising results from its ongoing Phase 1b clinical study of PH-762, with two patients achieving complete tumor clearance. The study evaluates the safety and tolerability of PH-762 for treating cutaneous squamous cell carcinoma and other skin cancers. There have been no significant adverse events related to the treatment, and the company expresses optimism about continued enrollment and potential for higher dosing in the trial.
Read more →PHIO▲ +5.6%on this news
Phio Pharmaceuticals Announces Publication in Clinical, Cosmetic and Investigational Dermatology
Phio Pharmaceuticals announced the publication of research on RXI-231, an INTASYL compound aimed at reducing hyperpigmentation by targeting the tyrosinase gene. The study demonstrated significant reductions in melanin content in both human melanocytes and a 3D epidermal model. Further clinical testing is needed, but the results suggest RXI-231 could be a promising treatment for hyperpigmentation disorders.
Read more →PHIO▲ +26.7%on this news
Phio Pharmaceuticals Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Phio Pharmaceuticals announced a registered direct offering of 240,000 shares of common stock priced at $2.00 per share. The aggregate gross proceeds are expected to reach $0.48 million, which will be used for working capital and other corporate purposes. Concurrently, unregistered warrants will be issued in a private placement, allowing the purchase of an equivalent number of shares at the same price. The closing of the offering is anticipated to occur on December 24, 2024, pending customary conditions.
Read more →PHIO▼ -30.7%on this newsshared move
Phio Pharmaceuticals Announces Positive Safety Monitoring Committee (SMC) Recommendation to Continue to Third Dose Cohort in its Clinical Study of PH-762
Phio Pharmaceuticals announced that its Safety Monitoring Committee recommended continuing to the third dose cohort in the Phase 1b clinical trial of PH-762, aimed at treating various skin cancers. The second cohort showed promising results, with two patients achieving complete tumor clearance. The treatment was well tolerated, with no serious adverse events reported.
Read more →PHIO▼ -30.7%on this newsshared move
Phio Pharmaceuticals Announces Positive Safety Monitoring Committee (SMC) Recommendation to continue to Third Dose Cohort in its Clinical Study of PH-762 -Phio's Lead Compound PH-762 demonstrates encouraging safety profi
Phio Pharmaceuticals has received a positive recommendation from the Safety Monitoring Committee to move forward with the third dose cohort in its Phase 1b clinical trial of PH-762. The trial assesses PH-762's safety and tolerability for treating cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma. Notably, the second cohort showed encouraging safety results with no dose-limiting toxicities, alongside promising efficacy data indicated by complete and partial tumor clearance in initial patients. The company plans to continue enrollment in this clinical study.
Read more →PHIO▼ -30.7%on this newsshared move
Phio Pharmaceuticals Announces $1.15 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Phio Pharmaceuticals has announced a registered direct offering of 437,192 shares of its common stock at a price of $2.635 per share, aiming to raise approximately $1.15 million. In concurrent private placements, the company will issue warrants exercisable at $2.51 per share. The closing of the offering is expected around December 20, 2024, subject to standard conditions. The funds raised are intended for working capital and other corporate purposes, highlighting Phio's ongoing efforts to advance its INTASYL siRNA gene silencing technology in fighting cancer.
Read more →PHIO▲ +6.3%on this news
Phio Pharmaceuticals Announces Publication in Frontiers in Immunology
Phio Pharmaceuticals has announced the publication of its manuscript on PH-762 in Frontiers in Immunology. This study presents preclinical data indicating that PH-762, which silences PD-1, shows promise in treating advanced skin cancers. The ongoing Phase 1b clinical trial has reported significant tumor clearance in patients with cutaneous squamous cell carcinoma.
Read more →PHIOPhio Pharmaceuticals is a Finalist for the Technology Disruptor of the Year Award
Phio Pharmaceuticals has been named a finalist for the Technology Disruptor of the Year Award at Advanced Therapies Week 2025 in Dallas. The award recognizes significant technological advancements in cell and gene therapy. Phio's nomination highlights its INTASYL siRNA technology, which has shown effective tumor clearance in recent clinical trials for skin cancers.
Read more →PHIO▲ +12.4%on this news
Phio Pharmaceuticals Announces Completion of Enrollment in Second Cohort in Phase 1b Dose-Escalating Clinical Study
Phio Pharmaceuticals has completed enrollment for the second cohort in its Phase 1b clinical trial for PH-762, a treatment for skin cancers. The trial has shown promising results, with one patient achieving complete tumor clearance and another showing significant reduction. The study aims to evaluate the safety and efficacy of PH-762 in patients with specific skin cancers.
Read more →PHIO▼ -5.1%on this newsshared move
. Phio Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update
Phio Pharmaceuticals has reported its financial results for Q3 2024, showing progress in its clinical trials for the lead candidate PH-762. The Phase 1b trial received a positive safety recommendation and has enrolled patients with skin cancers. Key findings indicate some patients experienced significant tumor reductions. However, the company also reported a decline in cash reserves and a net loss compared to the previous year.
Read more →PHIOPhio Pharmaceuticals Announces Upcoming Presentation at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
Phio Pharmaceuticals announced it will present clinical data from its ongoing Phase 1b trial at the 39th Annual Meeting of the Society for Immunotherapy of Cancer. The trial evaluates the safety of PH-762, an intratumoral injection for treating skin cancers. Preliminary results indicate positive responses in some patients, with no serious adverse events reported.
Read more →PHIOPhio Pharmaceuticals Announces Upcoming Presentation at the 39 th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) Presenting new clinical data from Phio's on-going Phase 1b trial
Phio Pharmaceuticals announced its upcoming presentation at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), where it will share clinical data from its ongoing Phase 1b trial. This trial investigates the safety and tolerability of PH-762, an intratumoral injection treatment for various skin cancers. So far, the treatment has been well tolerated among enrolled patients, with no significant adverse events reported. The trial's enrollment is expected to complete by Q3 2025.
Read more →PHIOCorrection to Registration Link to Access Phio Pharmaceuticals’ Presentation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
Phio Pharmaceuticals Corp. will present at the Renmark Financial Communications Virtual Non-Deal Roadshow on October 23, 2024. CEO Robert Bitterman will lead the presentation, which aims to inform stakeholders about the company's proprietary INTASYL siRNA technology. Attendees can register for the event through a corrected link provided in the announcement.
Read more →PHIO▲ +9.8%on this news· ran to +20% by day 1shared move
Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-deal Roadshow Series
Phio Pharmaceuticals Corp. will participate in a virtual non-deal roadshow on October 23, 2024, at 12 PM EDT. CEO Robert Bitterman will present the company's proprietary INTASYL siRNA technology, which aims to enhance immune cell effectiveness against tumors. Stakeholders and investors are invited to register for the event.
Read more →PHIO▲ +17.8%on this newsshared move
Phio Pharmaceuticals Presenting Data on Its INSTAYL Compound PH-894 at ASGCT’s 2024 Advancing Gene and Cell Therapies for Cancer Conference
Phio Pharmaceuticals is presenting data on its INTASYL compound PH-894 at the ASGCT 2024 conference. The compound enhances the effectiveness of Natural Killer (NK) cells by silencing BRD4, boosting NK cell proliferation, and improving cytotoxic potential. PH-894 is positioned as a foundation for future immunotherapies targeting NK cells.
Read more →PHIO▼ -6.2%on this news· ran to -17% by day 3
Phio Announces Data Showcasing INTASYL’s Role in Helping Immune Cells Target and Kill Cancer Cells
Phio Pharmaceuticals announced data on its INTASYL platform, showcasing its ability to enhance immune cell efficacy in targeting and killing cancer cells. The INTASYL compounds, which silence specific genes, improve the functionality of adoptive cell therapies like NK, TIL, and CAR-T. The data will be presented at the 20th Annual Oligonucleotide Therapeutics Society Meeting in Montreal.
Read more →PHIOPhio Pharmaceuticals Announces Upcoming Presentation at ASGCT’s 2024 Advancing Gene + Cell Therapies for Cancer Conference
Phio Pharmaceuticals Corp. announced its upcoming presentation at the ASGCT's 2024 Advancing Gene + Cell Therapies for Cancer conference. The focus will be on its INTASYL compound PH-894, which targets BRD4 to enhance Natural Killer (NK) cell activation for Adoptive Cell Therapy. The conference is scheduled for October 16-17, 2024, in Philadelphia.
Read more →PHIOINTASYL Technology and Compounds to be Focus of Presentation at 20th Annual Meeting of Oligonucleotide Therapeutics Society
Phio Pharmaceuticals Corp. will present data on its INTASYL technology at the 20th Annual Oligonucleotide Therapeutics Society Meeting in Montreal from October 6-9. The presentation will focus on how INTASYL can enhance the functionality of adoptive cell therapies. This proprietary technology aims to improve the efficacy and tolerability of treatments targeting tumor cells.
Read more →PHIOPhio Pharmaceuticals Announces Presentation at the 9th Annual CAR-TCR Summit in Boston, MA
Phio Pharmaceuticals announced its participation in the 9th Annual CAR-TCR Summit in Boston, where it will present data on its INTASYL self-delivering RNAi technology. This innovative platform aims to enhance the effectiveness of immune cells in targeting tumor cells, improving overall treatment yield. The summit will take place from September 17-20, 2024.
Read more →PHIO▲ +6.1%on this news
Phio Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Phio Pharmaceuticals Corp. will present at the H.C. Wainwright 26th Annual Global Investment Conference from September 9-11, 2024. CEO Robert Bitterman will discuss the company's INTASYL technology and the Phase 1b clinical trial of its lead compound, PH-762. The presentation will be available for streaming, and one-on-one meetings will be held during the conference.
Read more →PHIOPhio Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update
Phio Pharmaceuticals has reported its financial results for the second quarter of 2024, showing a net loss of $1.8 million, reduced from $2.5 million in the same period last year. The company has also seen a decrease in research and development expenses attributed to cost rationalization efforts. Additionally, Phio entered into agreements to exercise existing warrants, generating approximately $2.6 million in net proceeds. However, its cash reserves decreased significantly, raising concerns about future operational capacity.
Read more →PHIOPhio Pharmaceuticals Announces Exploratory Collaboration with a Luxury Skin Care Company for Phio’s Patented INTASYL Compound
Phio Pharmaceuticals has announced an exploratory collaboration with a leading luxury skincare company to explore the use of its INTASYL compound for skin care applications. This collaboration signifies a potential expansion of INTASYL's applications beyond immuno-oncology. CEO Robert Bitterman emphasized the versatility of the INTASYL technology, which now has a substantial patent portfolio.
Read more →PHIO▼ -7.3%on this newsshared move
Phio Pharmaceuticals Announces New Chief Financial Officer
Phio Pharmaceuticals has appointed Robert M. Infarinato as its new Chief Financial Officer, effective August 1, 2024. Infarinato brings over 20 years of experience in financial leadership, having previously held significant roles in various healthcare organizations. CEO Robert Bitterman expressed confidence in Infarinato's ability to contribute to the company's growth and success.
Read more →PHIO▼ -7.3%on this newsshared move
Phio Pharmaceuticals Announces New Chief Financial Officer MARLBOROUGH, Massachusetts - (Newsfile Corp.
Phio Pharmaceuticals has appointed Robert M. Infarinato as its new Chief Financial Officer, effective August 1, 2024. Infarinato brings over 20 years of financial leadership experience, having previously served in key positions at several health care organizations. He will oversee essential functions such as accounting, finance, and investor relations at Phio. The company is focused on developing its INTASYL siRNA gene silencing technology, which aims to improve immune responses in cancer treatment.
Read more →PHIO▼ -13.6%on this news
Phio Pharmaceuticals Announces Exercise of Warrants for $3.1 Million Gross Proceeds
Phio Pharmaceuticals has announced the exercise of warrants, resulting in approximately $3.1 million in gross proceeds. The company will issue new unregistered warrants alongside the exercised shares, which will be used for working capital and general corporate purposes. The offering is expected to close on July 12, 2024, pending customary conditions.
Read more →PHIO▼ -13.6%on this newsshared move
Phio Pharmaceuticals Announces Exercise of Warrants for $3.1 Million Gross Proceeds MARLBOROUGH, Massachusetts - (Newsfile Corp.
Phio Pharmaceuticals announced the exercise of outstanding warrants, generating approximately $3.1 million in gross proceeds. The warrants, originally issued between February 2020 and December 2023, will be exercised at a reduced price of $5.45 per share. Proceeds from the exercise will be utilized for working capital and general corporate purposes. The completion of this offering is expected around July 12, 2024, subject to standard closing conditions.
Read more →PHIO▲ +9.1%on this news
Phio Pharmaceuticals Announces Addition of Clinical Trial Site for its Phase 1b study of PH-762
Phio Pharmaceuticals has announced the addition of the University of Pittsburgh Medical Center as a clinical trial site for its Phase 1b study of PH-762. The study, which has received a positive safety recommendation, is currently enrolling patients for its second cohort. PH-762 aims to improve immune cell effectiveness against various skin cancers.
Read more →PHIOPhio Pharmaceuticals Terminates Share Purchase Agreement with Triton Funds
Phio Pharmaceuticals has announced the termination of its share purchase agreement with Triton Funds, which allowed Triton to acquire up to 18.8% of the company's common stock. This decision raises concerns about the company's financial health and future funding opportunities. Phio is known for its INTASYL® siRNA gene silencing technology aimed at enhancing immune cell efficacy against tumors.
Read more →PHIOPhio Pharmaceuticals Terminates Share Purchase Agreement with Triton Funds MARLBOROUGH, Massachusetts--(Newsfile Corp.
Phio Pharmaceuticals Corp. has announced the termination of its share purchase agreement with Triton Funds LP, which allowed Triton the option to acquire up to 18.8% of the company's stock. This decision may affect the company’s financial standing and investor relations. Phio specializes in immuno-oncology therapeutics through its INTASYL siRNA technology.
Read more →PHIO▼ -9.2%on this newsshared move
Phio Pharmaceuticals Announces Reverse Stock Split MARLBOROUGH, Mass. (Newsfile Corp.
Phio Pharmaceuticals announced a reverse stock split at a ratio of 1-for-9, effective July 5, 2024, to raise its stock price above the $1.00 minimum bid requirement for listing on the Nasdaq. This action will reduce the outstanding common stock from approximately 4.6 million shares to about 0.5 million shares, with no change to the par value. The decision reflects the company’s ongoing efforts to maintain compliance with exchange regulations while supporting their innovative cancer treatment technologies.
Read more →PHIOPhio Pharmaceuticals Announces New Patent for INTASYL Compound That Targets Photo-aging
Phio Pharmaceuticals has received a patent in South Korea for its INTASYL compound RXI-185, aimed at treating photo-aging by slowing collagen breakdown caused by UV exposure. This patent expands Phio's portfolio, which now includes 81 patents, primarily focused on their siRNA gene silencing technology. The CEO emphasized the importance of this patent in relation to their ongoing skin cancer treatment initiatives.
Read more →PHIOPhio Pharmaceuticals Announces Positive Recommendation from Safety Monitoring Committee (SMC) of Phase 1b Clinical Study of Phio’s Lead Compound PH-762
Phio Pharmaceuticals announced a positive recommendation from the Safety Monitoring Committee for its Phase 1b clinical study of PH-762. The initial cohort showed an encouraging safety profile with no dose-limiting toxicities. The study will now proceed to the next dose concentration, indicating progress in the development of this cancer therapy.
Read more →PHIOPhio Pharmaceuticals Announces Positive Recommendation from Safety Monitoring Committee (SMC) of Phase 1b Clinical Study of Phio's Lead Compound PH-762 -Intratumoral PH-762 has encouraging safety profile in the initial c
Phio Pharmaceuticals has received a positive recommendation from the Safety Monitoring Committee for its Phase 1b clinical study of the compound PH-762. The committee approved the escalation to the next dose concentration after reviewing data indicating no dose-limiting toxicities or significant adverse events in the initial patient cohort. This study focuses on evaluating the safety and tolerability of PH-762 for treating various stages of cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma. The company expresses optimism about the future development of this therapy.
Read more →PHIOPhio Pharmaceuticals Announces Presentation at the Annual Meeting of the American Society of Clinical Oncology (ASCO)
Phio Pharmaceuticals announced it will present data on its lead candidate, PH-762, at the ASCO annual meeting. The presentation will cover the completion of the first dose cohort in an ongoing Phase 1b study evaluating PH-762's safety and tolerability for treating cutaneous squamous cell carcinoma and other skin cancers. The company believes this therapy could offer significant clinical benefits to patients.
Read more →PHIO▲ +7.4%on this news
Phio Pharmaceuticals Secures New Investor
Phio Pharmaceuticals announced a purchase agreement with TRITON Funds, which will purchase up to 18.8% of Phio's common shares, providing the company with up to $621,000 in gross proceeds. This investment reflects TRITON's belief in Phio's proprietary INTASYL siRNA technology, designed to improve the efficacy of immune cells against tumor cells. The deal underscores confidence in Phio's potential, as the company continues to develop innovative treatments in the oncology space.
Read more →PHIO▲ +7.4%on this news
Phio Pharmaceuticals Secures New Investor --Fund invests in microcap equities
Phio Pharmaceuticals has entered into a purchase agreement with TRITON Funds, securing an investment that will allow the purchase of up to approximately 18.8% of its common shares. This agreement will yield gross proceeds of up to $621,000, which the company expects to bolster the advancement of its proprietary INTASYL siRNA gene silencing technology aimed at improving immune cell effectiveness against tumors. Both parties expressed optimism regarding the collaboration, with TRITON highlighting the potential of Phio's innovative approach and management. The announcement indicates growing recognition for Phio's technology within the biopharma sector.
Read more →PHIO▼ -8.5%on this newsshared move
Phio Pharmaceuticals Presents This Week at the Society for Investigative Dermatology (SID)
Phio Pharmaceuticals Corp. is showcasing its lead clinical candidate, PH-762, at the Society for Investigative Dermatology meeting. PH-762, part of Phio's INTASYL siRNA gene silencing technology, aims to target and silence PD-1 to improve T cell efficacy against skin carcinomas. The company reported encouraging preclinical results, indicating robust tumor growth inhibition and good tolerability. This candidate is currently being evaluated in a Phase 1b clinical trial for various skin cancers.
Read more →PHIO▲ +9%on this newsshared move
Phio Pharmaceuticals Announces Completion of Dosing in First Patient Cohort in PH-762 Phase 1b Dose-Escalation Study
Phio Pharmaceuticals has completed dosing in the first cohort of its Phase 1b clinical trial for PH-762, targeting skin carcinomas. The ongoing trial aims to evaluate the safety and tolerability of PH-762, a promising treatment leveraging Phio's INTASYL siRNA technology. Screening for the next dosing cohort is currently in progress. CEO Robert Bitterman expressed excitement about the potential of PH-762 to provide new treatment options for patients.
Read more →PHIO▼ -8.3%on this news
Phio Pharmaceuticals Reports Q1 2024 Results and Provides Business Update
Phio Pharmaceuticals reported its Q1 2024 results, highlighting progress in its Phase 1b clinical trial for PH-762, with three patients enrolled. The company presented new data on its INTASYL technology at significant conferences, showcasing its potential in immunotherapy. Financially, Phio experienced a decrease in both cash reserves and net loss compared to the previous year, reflecting improved cost management.
Read more →PHIOPhio Pharmaceuticals Reports Q1 2024 Results and Provides Business Update -Four sites across the country participating in Phase 1b clinical trial for lead product candidate PH-762 -Three patients have been enrolled
Phio Pharmaceuticals Corp. has reported its Q1 2024 financial results and business updates amid ongoing clinical developments. The company is currently conducting a Phase 1b clinical trial for its lead product candidate PH-762, with three patients enrolled across four sites. Financially, Phio has managed to reduce research and development expenses significantly while narrowing its net loss compared to the same quarter last year, despite a decline in cash reserves.
Read more →PHIOPhio Pharmaceuticals Announces Upcoming Presentation at the Annual Meeting of the Society of Clinical Oncology (ASCO)
Phio Pharmaceuticals has announced that it will present new data on its lead product candidate, PH-762, at the upcoming Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago. The presentation will showcase a Phase 1b clinical trial evaluating the safety and efficacy of PH-762 for treating specific stages of skin cancers, including cutaneous squamous cell carcinoma and melanoma. This highlight reflects Phio's commitment to addressing significant unmet medical needs within the oncology space.
Read more →PHIO▲ +29.7%on this news
Intratumoral Injection of Phio’s PH-762 significantly inhibits tumor growth in murine tumor models and may generate memory-specific T cells
Phio Pharmaceuticals announced promising preclinical results for PH-762, demonstrating significant tumor growth inhibition in murine models and good tolerability. The compound's ability to silence PD-1 mRNA may enhance immune response, generating memory-specific T cells. These findings support its ongoing clinical trial as a neoadjuvant therapy for various skin cancers.
Read more →PHIOPhio Pharmaceuticals Announces Upcoming Presentations at the 81st Annual Meeting of the Society for Investigative Dermatology (SID)
Phio Pharmaceuticals Corp. announced that it will present new data on its lead candidate, PH-762, at the 81st Annual Meeting of the Society for Investigative Dermatology on May 16, 2024. The presentations will include three posters detailing the potential of INTASYL technology in treating skin cancers. PH-762 is currently in a Phase 1 clinical trial aimed at evaluating its safety and efficacy in patients with various stages of cutaneous squamous cell carcinoma and melanoma.
Read more →PHIOPhio Pharmaceuticals Announces Upcoming Presentation at the 27th Annual Meeting of the American Society of Cell and Gene Therapy (ASCGT)
Phio Pharmaceuticals Corp. has announced it will present new data on its lead clinical candidate, PH-762, at the 27th Annual Meeting of the ASCGT in Baltimore on May 8, 2024. The INTASYL™ siRNA compound is showing effectiveness in silencing PD-1 and enhancing immune response against tumor growth, particularly in specific skin cancer cases. The presentation will occur within the session on Cancer-Immunotherapy and Cancer Vaccines, highlighting the company's focus on immunooncology therapies.
Read more →PHIONational Spotlight Features Phio’s Innovative RNAi Technology Platform
Phio Pharmaceuticals Corp. announced that its INTASYL siRNA technology will be featured in a national program hosted by Dennis Quaid, airing on PBS and Fox Business Network in April. This coverage aims to showcase the technology's potential in enhancing immune cell effectiveness against tumors. The INTASYL platform is noted for its unique self-delivery mechanism in immuno-oncology.
Read more →PHIOPhio Pharmaceuticals Reports 2023 Year End Financial Results and Provides Business Update
Phio Pharmaceuticals reported its 2023 financial results, highlighting significant progress in its clinical trials for PH-762, an immuno-oncology treatment. The company received FDA clearance for a Phase 1B trial targeting various skin cancers and has filed new patents to enhance its treatment portfolio. Despite a net loss of $10.8 million, the company is focused on advancing its lead candidate while implementing cost rationalization measures.
Read more →PHIOPhio Pharmaceuticals Reports 2023 Year End Financial Results and Provides Business Update -Four sites across the country participating in clinical trial for lead product candidate PH-762 -Two patients have already comple
Phio Pharmaceuticals reported its financial results for the year ending December 31, 2023, highlighting progress in clinical trials for its lead product candidate PH-762, which aims to treat various forms of skin cancer. The company has gained FDA clearance to initiate a Phase 1B trial and has begun treatment with two patients, both of whom completed the regimen without reported adverse events. Additionally, Phio has secured new patents to bolster its work in dermatological treatments. However, the company reported a decline in cash reserves and a 10% reduction in research and development expenses due to strategic shifts.
Read more →PHIO▼ -21.5%on this news· ran to -32% by day 1
Phio Pharmaceuticals Presenting Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological Malignancies
Phio Pharmaceuticals Corp. unveiled promising new data for its INTASYL siRNA technology at the 10th Immunotherapy of Cancer Conference in Munich. The data highlights INTASYL's ability to enhance natural killer (NK) cell function by silencing Cbl-b, a protein that limits NK cell activation. This preclinical evidence suggests that INTASYL may significantly improve adoptive cell therapy for patients with hematological malignancies, thereby making it a potentially effective treatment option. The presentation is scheduled to take place on March 21-22, 2024, showcasing advancements in immuno-oncology therapeutics.
Read more →PHIOPhio Pharmaceuticals Announces Addition of Clinical Trial Sites at Banner MD Anderson Cancer Center, The George Washington University, and Integrity Research
Phio Pharmaceuticals has announced the inclusion of three additional clinical trial sites for its Phase 1b study of PH-762, focused on treating skin cancers. The newly added sites are located at the George Washington University, Banner MD Anderson Cancer Center, and Integrity Research Clinical Associates. This expansion aims to improve patient recruitment and reinforce the trial's credibility through esteemed institutions. PH-762 is designed to silence PD-1, potentially enhancing the efficacy of T cells against tumor cells.
Read more →PHIO▲ +6.6%on this news· ran to +19% by day 3
Phio Pharmaceuticals Announces Patent Granted by USPTO, Strengthening the Company’s Intellectual Property Position in Treating Aging Skin and Skin Disorders
Phio Pharmaceuticals announced the granting of a new patent by the USPTO for its INTASYL compounds, RXI-185 and RXI-231, which are designed to treat age-related skin disorders. The compounds target specific proteins involved in skin aging and pigmentation. This patent enhances Phio's intellectual property position, complementing its ongoing initiatives in treating skin cancer.
Read more →PHIO▲ +6.6%on this news· ran to +19% by day 3shared move
Phio Pharmaceuticals Announces Patent Granted by USPTO, Strengthening the Company’s Intellectual Property Position in Treating Aging Skin and Skin Disorders
Phio Pharmaceuticals has received a patent grant from the USPTO for its INTASYL compounds RXI-185 and RXI-231, aimed at treating age-related skin disorders like photo-aging and dermal hyperpigmentation. This patent enhances the company's intellectual property position and complements its ongoing projects in the field of skin cancer treatment. RXI-185 silences MMP1 expression to prevent collagen breakdown, while RXI-231 targets tyrosinase for effective pigmentation treatment. Overall, the patent reinforces Phio's robust portfolio in the biotechnology sector.
Read more →PHIOPhio Pharmaceuticals Announces Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological Malignancies
Phio Pharmaceuticals Corp. has announced new preclinical data suggesting that its INTASYL technology, designed to enhance immune cell effectiveness, may improve natural killer (NK) cell activity for treating hematological malignancies. This data will be presented at the 10th Immunotherapy of Cancer Conference in Munich, Germany, from March 21-23, 2024. The study focuses on targeting Cbl-b to boost cytotoxicity against tumor cells, highlighting the innovative approach of self-delivering siRNA technology in immuno-oncology.
Read more →PHIO▼ -42.1%on this news
Phio Pharmaceuticals Announces Exercise of Warrants for $2.8 Million Gross Proceeds
Phio Pharmaceuticals has announced the exercise of outstanding warrants, resulting in gross proceeds of approximately $2.8 million. Several accredited investors are involved in this agreement, with warrant exercise prices set at a reduced rate of $1.33 per share. The transaction is expected to close on or around December 8, 2023, and the company plans to use the proceeds for working capital and corporate purposes. Additionally, new unregistered warrants will be issued to investors in this private placement.
Read more →PHIO▼ -10.5%on this news
Phio Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update
Phio Pharmaceuticals reported its financial results for the third quarter of 2023, highlighting the enrollment of its first patient in the PH-762 clinical trial targeting skin cancers. The company also presented new data on its INTASYL compounds at major oncology conferences. Financially, Phio registered a net loss of $2.8 million, with total cash reserves declining from previous levels. Decreases in research and administrative expenses were noted, reflecting ongoing efficiency efforts despite the financial losses.
Read more →PHIO▼ -10.5%on this news
Phio Pharmaceuticals Announces First US Patient Enrolled in Phase 1B Clinical Trial with Intratumoral PH-762 anti-PD-1 Therapy for Treatment of Skin Carcinomas
Phio Pharmaceuticals Corp. has announced the enrollment of the first patient in its Phase 1b clinical trial for PH-762, an anti-PD-1 therapy aimed at treating skin carcinomas. The trial will evaluate the safety, tolerability, and efficacy of intratumorally injected PH-762 in patients with cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma. This study, utilizing the company's proprietary INTASYL RNAi platform, marks a significant step in their development of a novel immuno-oncology treatment. Enrollment will include up to 30 patients across multiple centers in the United States.
Read more →PHIO▲ +6.6%on this news
Phio Pharmaceuticals Presents New Data Showing INTASYL Compound targeting CTLA-4 Enhances Tumor Control
Phio Pharmaceuticals Corp. recently presented promising preclinical data at the 38th Annual Meeting of the Society for Immunotherapy of Cancer, showcasing the effectiveness of their INTASYL RNAi compound targeting CTLA-4. The data indicated that the combination of INTASYL and systemic anti-PD-1 therapy resulted in significant tumor regression and enhanced immune response in a mouse model. This research highlights the potential of INTASYL as a novel strategy in enhancing the efficacy of immune checkpoint therapies.
Read more →PHIO▼ -32.3%on this news· ran to -47% by day 3
Phio Pharmaceuticals Announces Upcoming Presentation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
Phio Pharmaceuticals Corp. announced the presentation of new preclinical data at the upcoming 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC). This data highlights the enhanced tumor control associated with an INTASYL compound targeting CTLA-4 when used in conjunction with a systemic anti-PD-1 antibody. The event will take place in San Diego from November 1-5, 2023. The presentation will also be accessible online after the event.
Read more →PHIO▲ +87.1%on this newsshared move
Phio Pharmaceuticals Presents New Data for Targeting of BRD4 with its INTASYL™ Compound PH-894
Phio Pharmaceuticals presented promising preclinical data for its INTASYL compound PH-894 at the AACR-NCI-EORTC Conference. The data indicates that PH-894 enhances the recognition of melanoma cells by immune cells and shows effectiveness in directly killing various human cancer cell lines. This positions PH-894 as a potential safer alternative for cancer treatment.
Read more →PHIO▲ +87.1%on this newsshared move
Phio Pharmaceuticals Presents New Data for Targeting of BRD4 with its INTASYL™ Compound PH-894
Phio Pharmaceuticals presented positive preclinical data for its INTASYL compound PH-894, indicating its ability to enhance melanoma cell recognition by immune cells and act as an effective antitumor agent. The findings suggest that PH-894 increases MART-1 expression, potentially improving T cell-mediated tumor destruction. Additionally, PH-894 demonstrated concentration-dependent apoptosis across various cancer cell lines. These results were shared at the AACR-NCI-EORTC International Conference on Cancer Therapeutics in Boston.
Read more →PHIOPhio CEO to Speak at Wainwright Conference in New York in September
Phio Pharmaceuticals announced that its President and CEO, Robert Bitterman, will present at the H.C. Wainwright 25th Annual Global Investment Conference in New York on September 11th. He will discuss the recent FDA IND approvals for their lead product, PH-762, which is cleared for two clinical trials. The company is focused on enhancing immune cell efficacy against tumors using its proprietary INTASYL RNAi platform. This presentation will also highlight the experienced leadership team now guiding the company through its development phase.
Read more →PHIOPhio Pharmaceuticals Announces Dosing of First Patient in Collaborative Clinical Trial with AgonOx, Inc. and Providence Cancer Institute
Phio Pharmaceuticals has announced the dosing of the first patient in a collaborative clinical trial with AgonOx, Inc. and Providence Cancer Institute. This trial aims to evaluate the safety and efficacy of AgonOx's AGX148 CD8 tumor-infiltrating lymphocytes in combination with Phio's PD-1 silencing PH-762 for treating melanoma and other advanced solid tumors. The trial is significant as it represents a step forward in the development of innovative immunotherapy treatments.
Read more →PHIOPhio Pharmaceuticals Announces Dosing of First Patient in Collaborative Clinical Trial with AgonOx, Inc. and Providence Cancer Institute Trial targeting treatment of metastatic melanoma and other solid tumors MARLBOROUGH
Phio Pharmaceuticals has announced the dosing of the first patient in a collaborative clinical trial with AgonOx, Inc. and Providence Cancer Institute. The trial will investigate the safety and potential benefits of using AgonOx's AGX148 ‘double positive’ CD8 tumor-infiltrating lymphocytes combined with Phio's PD-1 silencing PH-762 in treating metastatic melanoma and other solid tumors. This initiative marks a significant step forward in the pursuit of innovative immunotherapy treatments against challenging malignancies.
Read more →PHIOPhio Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update
Phio Pharmaceuticals Corp. has reported its financial results for the second quarter of 2023, revealing a net loss of $2.5 million. The company has received FDA clearance for an Investigational New Drug application for PH-762 and is initiating a Phase 1b clinical trial to evaluate its safety and tumor response in skin cancers. Despite a decrease in cash reserves, the company's ongoing research highlights its commitment to developing effective cancer therapies using their INTASYL RNAi platform.
Read more →PHIO▼ -13.2%on this news
Phio Pharmaceuticals Announces $4 Million Concurrent Registered Direct Offering and Private Placement Priced At-the-Market Under Nasdaq Rules
Phio Pharmaceuticals has announced a $4 million funding round through a registered direct offering and a private placement. The company will issue a total of 934,581 shares at $4.28 each, along with warrants to purchase additional shares. The proceeds from these offerings are intended for developing its immuno-oncology programs and general corporate purposes. The offerings are set to close around June 2, 2023, subject to customary conditions.
Read more →PHIOPhio Pharmaceuticals Announces Initiation of Collaborative Clinical Trial with PH-762, AgonOx's Tumor Infiltrating Lymphocyte Program (AGX148) and Providence Cancer Institute One of two newly announced clinical trials fo
Phio Pharmaceuticals has announced the initiation of a clinical trial for its lead product candidate, PH-762, in collaboration with AgonOx and Providence Cancer Institute. The trial aims to assess the safety and therapeutic benefits of PH-762 combined with tumor-infiltrating lymphocytes in patients with melanoma and advanced solid tumors. This follows recent FDA clearance for initiating another clinical trial focused on different cancer types. Phio's proprietary INTASYL RNAi technology aims to enhance immune cell efficacy against tumors.
Read more →PHIO▲ +21.4%on this news
Phio Pharmaceuticals Announces FDA Clearance to Initiate Clinical Trial of PH-762 for Treatment of Skin Carcinomas
Phio Pharmaceuticals announced that the U.S. FDA has cleared its Investigational New Drug application to begin a clinical trial for PH-762, targeting skin carcinomas. This trial will evaluate the safety, tolerability, and efficacy of intratumoral PH-762 in patients with conditions like cutaneous squamous cell carcinoma and melanoma. The company intends to initiate the Phase 1b trial in the second half of 2023, marking a key step in its clinical development path following drug discovery. Phio's strategy includes focusing on this U.S. clinical trial while winding down a prior trial in France.
Read more →PHIOPhio Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update
Phio Pharmaceuticals reported its financial results for Q1 2023, revealing a net loss of approximately $3.6 million. The company plans to initiate a Phase 1 clinical trial in adoptive cell therapy in partnership with AgonOx. Promising data from preclinical studies indicate that the intratumoral administration of its INTASYL technology is effective at generating an anti-tumor immune response. However, rising research and administrative costs have contributed to an increased overall net loss compared to the previous year.
Read more →PHIO▼ -19.2%on this news· ran to -37% by day 3
Phio Pharmaceuticals Presents Preclinical Data Demonstrating Synergy-Enhanced in vivo Anti-Tumor Efficacy of PD-1/CTLA-4 Dual-Targeting INTASYL - Data to be presented at American Association for Cancer Research (AACR) An
Phio Pharmaceuticals has presented preclinical data indicating that their INTASYL formulation, designed to target PD-1 and CTLA-4 in tumor cells, exhibits enhanced anti-tumor efficacy in vivo compared to single-target therapies. The data, presented at the AACR Annual Meeting, suggests the dual-targeting strategy may offer a safer alternative to systemic use of such combinations, as the treatment was well tolerated in animal studies. The company emphasizes that the findings are based on current expectations and are subject to various uncertainties.
Read more →PHIO▼ -19.2%on this news· ran to -37% by day 3
Phio Pharmaceuticals Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules Marlborough, Mass.
Phio Pharmaceuticals Corporation announced a registered direct offering to sell 353,983 shares at $5.65 per share, bringing in approximately $2 million. The offering aims to fund the company's immuno-oncology programs and general corporate purposes. Alongside the shares, the company will issue unregistered warrants as part of a concurrent private placement. The closing of this offering is subject to customary conditions and is expected to take place around April 20, 2023.
Read more →PHIO▲ +18.5%on this newsshared move
Phio Pharmaceuticals Presents Preclinical Study Showing PH-762 Induces Systemic Memory T Cell Mediators of Anti-Tumor Immunity - Data to be presented at American Association for Cancer Research (AACR) Annual Meeting 2023
Phio Pharmaceuticals announced positive results from a preclinical study on PH-762, showing that it induces systemic memory T cell mediators of anti-tumor immunity. The study suggests that intratumoral administration can effectively generate a local anti-tumor immune response and systemic tumor-specific memory T cells in a hepatocellular carcinoma model. These findings may support the clinical use of PH-762 in treating melanoma, and the data will be presented at the upcoming AACR Annual Meeting 2023.
Read more →PHIOPhio Pharmaceuticals Reports 2022 Year End Financial Results and Provides Business Update - Following safety data review by the DMC, enrollment is now open for the second cohort of its Phase 1b study of PH-762 for the tr
Phio Pharmaceuticals has reported its financial results for year-end 2022, noting enrollment opening for the second cohort of its Phase 1b study of PH-762 for advanced melanoma. The company received FDA confirmation to initiate a new Phase 1 clinical trial in collaboration with AgonOx. Despite reductions in operating loss and R&D expenses, Phio's cash has decreased significantly from the previous year. The company remains focused on advancing its proprietary INTASYL RNAi technology and anticipates further updates in the coming months.
Read more →PHIOPhio Pharmaceuticals Appoints Robert Bitterman as President and Chief Executive Officer
Phio Pharmaceuticals has appointed Robert Bitterman as President and Chief Executive Officer, effective February 20, 2023. Bitterman, who previously served as Interim CEO since September 2022, has proven to be an effective leader according to the Board of Directors. His leadership experience and knowledge of Phio's pipeline position him well to advance the company's clinical programs and drive shareholder growth. The company is focused on achieving key preclinical and clinical milestones in the coming years.
Read more →PHIO▼ -6.4%on this news
Phio Pharmaceuticals Announces Reverse Stock Split
Phio Pharmaceuticals Corp. has announced a reverse stock split of its common stock at a ratio of 1-for-12, effective January 26, 2023. The decision aims to raise the share price to meet Nasdaq's minimum bid price requirement of $1.00 for continued listing. The reverse split will decrease the number of outstanding shares from approximately 13.7 million to about 1.1 million, with no change to the par value. Shareholders will receive cash payments for any fractional shares resulting from the split.
Read more →PHIO▲ +40.3%on this news
www.phiopharma.com I Ticker: PHIO (NASDAQ) Phio Pharmaceuticals Proprietary Innovations in Immuno - oncology (I/O) Therapeutic Applications 2 This presentation contains forward - looking statements within the meaning of
Phio Pharmaceuticals, led by Nobel Laureate Craig Mello, is focusing on proprietary immuno-oncology therapies using its INTASYL technology. This technology effectively silences genes that tumors use to evade immune responses, positioning the company in a potentially lucrative solid tumor treatment market projected to reach $123 billion in revenue. The company has partnerships to enhance its development efforts, though it acknowledges inherent risks and uncertainties affecting its business outlook. The incidence of challenging cancers like cutaneous squamous cell carcinoma and melanoma reinforces the need for innovative treatments.
Read more →PHIOPhio Pharmaceuticals Announces New Clinical Program to Study PH-762 for the Treatment of Cutaneous Squamous Cell Carcinoma Marlborough, Mass.
Phio Pharmaceuticals Announces New Clinical Program to Study PH-762 for the Treatment of Cutaneous Squamous Cell Carcinoma Marlborough, Mass., December 21, 2022/PR Newswire/-- Phio Pharmaceuticals Corp., today announced it expects to file an IND in the US in the first half o
Read more →PHIO▼ -7.1%on this news· ran to -23% by day 3
Phio Announces New Appointments to Leadership Team, Reports on Third Quarter 2022 Financial Results and Provides Business Update New executive team leading development of Phio's RNAi compounds and proprietary INTASYL pla
New Appointments to Leadership Team, Reports on Third Quarter 2022 Financial Results and Provides Business Update New executive team leading development of Phio's RNAi compounds and proprietary INTASYL platform Continuing enrollment in its Phase 1b study of PH-762 for the t
Read more →PHIO▼ -5.2%on this news
Phio Pharmaceuticals Announces Appointment of Robert Bitterman as Executive Chairman
Phio Pharmaceuticals Announces Appointment of Bitterman as Executive Chairman MARLBOROUGH, Mass., Sept. 29, 2022 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company developing the next generation of therapeutics based on its propri
Read more →PHIOPhio Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update Initiated dosing of subjects and enrollment ongoing in the first-in-human clinical study of PH-762 for the treatment of adva
Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update subjects and enrollment ongoing in the first-in-human clinical study of PH-762 for the treatment of advanced melanoma; expect to announce top-line data from the first group of subjects in
Read more →PHIOPhio Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update First-in-human clinical study of PH-762 for the treatment of advanced melanoma open for enrollment Expect to finalize IND-ena
Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update First-in-human clinical study of PH-762 for the treatment of advanced melanoma open for enrollment IND-enabling studies for PH-894 in the second half of 2022 Marlborough, Mass., March 12
Read more →PHIOPhio Pharmaceuticals Reports 2021 Year End Financial Results and Provides Business Update Company transitioning into a clinical stage company with start of the first clinical study for lead program, PH-762. Marlborough,
Pharmaceuticals Reports 2021 Year End Financial Results and Provides Business Update Company transitioning into a clinical stage company with start of the first clinical study for lead program, PH-762. Marlborough, Mass., March 22, 2022/PRNewswire/ -- Phio Pharmaceuticals Cor
Read more →PHIOSent via Electronic Delivery to: gdispersyn@phiopharma.com; ckontulis@phiopharma.com
Sent via Electronic Delivery to: gdispersyn@phiopharma.com; ckontulis@phiopharma.com Mr. Gerrit Dispersyn and Chief Executive Officer Phio Pharmaceuticals Corp. 257 Simarano Drive, Suite 101 Marlborough, Massachusetts 01752 Re: Phio Pharmaceuticals Corp. (the "Company") Na
Read more →PHIOPhio Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update Lead program, PH-762, is on track to enter first-in-human clinical study in Q1 2022 Presented data at the ESMO Congress 2021
Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update Lead program, PH-762, is on track to enter first-in-human clinical study in Q1 2022 Presented data at the ESMO Congress 2021 showing Dual-Targeting INTASYL PH-3861 induced a durable and
Read more →PHIOPhio Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Update Marlborough, Mass.
Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Update Marlborough, Mass., August 12, 2021/PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based
Read more →PHIOPhio Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business Update Marlborough, Mass.
Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business Update Marlborough, Mass., May 13, 2021 -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprieta
Read more →PHIOPhio Pharmaceuticals Reports 2020 Year End Financial Results and Provides Business Update Marlborough, Mass.
Phio Pharmaceuticals Reports 2020 Year End Financial Results and Provides Business Update Marlborough, Mass., March 25, 2021 - Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its propri
Read more →PHIOPhio Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Business Update Marlborough, Mass.
Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Business Update Marlborough, Mass., November 10, 2020 -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its pro
Read more →PHIOPhio Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Business Update Marlborough, Mass.
Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Business Update Marlborough, Mass., August 12, 2020 -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its pro
Read more →PHIOPhio Pharmaceuticals Reports Year End 2019 Financial Results and Provides Business Update Marlborough, Mass.
Phio Pharmaceuticals Reports Year End 2019 Financial Results and Provides Business Update Marlborough, Mass., March 26, 2020 -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its propr
Read more →PHIOPhio Pharmaceuticals and Helmholtz Zentrum M nchen Announce Collaboration and Option Agreement with Medigene Marlborough, Mass., USA and Martinsried/Munich
Phio Pharmaceuticals and Helmholtz Zentrum M nchen Announce Collaboration and Option Agreement with Medigene USA and Martinsried/Munich, March 10, 2020 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-
Read more →PHIOPhio Pharmaceuticals Announces Pricing of $8.0 Million Underwritten Public Offering
Phio Pharmaceuticals Announces Pricing of $8.0 Million MARLBOROUGH, Mass., February 11, 2020 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-deliver
Read more →PHIOStanley Higgins Senior Director Listing Qualifications The Nasdaq Stock Market LLC +1 301 978 8041 Sent via Electronic Delivery to: gdispersyn@phiopharma.com , ckontulis@phiopharma.com , RMurr@gibsondunn.com
Listing Qualifications The Nasdaq Stock Market LLC Sent via Electronic Delivery to: gdispersyn@phiopharma.com, ckontulis@phiopharma.com, RMurr@gibsondunn.com Dr. Gerrit Dispersyn, Med. Sc. President and Chief Executive Officer Phio Pharmaceuticals Corp 257 Simarano Drive,
Read more →PHIOPhio Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Business Update
Phio Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Business Update MARLBOROUGH, Mass., November 12, 2019 /PRNewswire/ -- Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeuti
Read more →PHIOPhio Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Business Update
Phio Pharmaceuticals Reports Second Results and Provides Business Update Mass., August 12, 2019 /PRNewswire/ - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delive
Read more →PHIOPhio Pharmaceuticals Reports First Quarter 2019 Financial Results and Corporate Highlights Expansion of Industry Partners With Glycostem Therapeutics BV Collaboration Dr. John A. Barrett Appointed as Chief Development Of
Pharmaceuticals Reports First Quarter 2019 Results and Corporate Highlights Mass., May 14, 2019 /PRNewswire/ - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delive
Read more →PHIOPhio Pharmaceuticals Reports Fourth Quarter and Year End 2018 Financial Results and Corporate Highlights Gerrit Dispersyn Appointed as President and Chief Executive Officer Cash Position Expected to Provide
Pharmaceuticals Reports Fourth Quarter and Year End 2018 Financial Results and Corporate Highlights Mass., March 27, 2019 /PRNewswire/ - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on it
Read more →PHIOPhio Pharmaceuticals Appoints Gerrit Dispersyn as New Chief Executive Officer Effective March 1 - CEO Geert Cauwenbergh to Retire and Remain on Board of Directors
Pharmaceuticals Appoints Gerrit Dispersyn as New Chief Executive Officer Effective March 1 CEO Geert Cauwenbergh to Retire and Remain on Board of Directors - MARLBOROUGH, Mass., Feb. 15, 2019 / PRNewswire / -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO) today announced that Gerr
Read more →PHIORXi Pharmaceuticals Corporation Changes Name to Phio Pharmaceuticals Corp. -Reflects Company's Transition to Develop Groundbreaking Immuno-Oncology Therapeutics- -Trading Under Nasdaq Symbol PHIO Begins Today, November 1
Corporation Changes Name to Phio Pharmaceuticals Corp. Transition to Develop Groundbreaking Immuno-Oncology Therapeutics- Under Nasdaq Symbol "PHIO" Begins Today, November 19- November 19, 2018 /PRNewswire/ Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a biotechnology company dev
Read more →PHIORXi Pharmaceuticals Reports Third Quarter 2018 Financial Results and Recent Corporate Highlights Appoints Gerrit Dispersyn as President and Chief Operating Officer, effective Today Geert Cauwenbergh to Remain CEO and Mem
Reports Third Quarter 2018 Financial Results and Recent Corporate Highlights November 14, 2018 /PRNewswire/ RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-deliv
Read more →PHIORXI PHARMACEUTICALS Announces Pricing of $15 Million UPSIZED UNDERWRITTEN Public Offering
PHARMACEUTICALS Announces Pricing of $15 Million UPSIZED UNDERWRITTEN Public Offering MARLBOROUGH, Mass., Oct. 1, 2018 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company developing the next generation of immuno-oncology therapeutics based o
Read more →PHIOThe Use of Self - delivering RNAi to Enhance NK Cell Cytotoxicity Melissa Maxwell, Dingxue Yan, James Cardia, Gerrit Dispersyn RXi Pharmaceuticals, Marlborough, MA, 01752 USA cell membrane RISC mRNA cleaved mRNA 1 2 3 4
The Use of Self - delivering RNAi to Enhance NK Cell Cytotoxicity Melissa Maxwell, Dingxue Yan, James Cardia, Gerrit Dispersyn RXi Pharmaceuticals, Marlborough, MA, 01752 USA cell membrane RISC mRNA cleaved mRNA 1 2 3 4 RNAi compound (sd - rxRNA) administered sd - rxRNA enters ce
Read more →PHIORXi Pharmaceuticals Reports Second Quarter 2018 Financial Results and Recent Corporate Highlights Extended cash runway by securing net proceeds of $4.2 million in April 2018 Announced positive results from dermatology an
Pharmaceuticals Reports Second Quarter 2018 Financial Results and Recent Corporate Highlights August 14, 2018 /PRNewswire/ RXi Pharmaceuticals Corporation (NASDAQ: RXII) a biotechnology company developing the next generation of immuno-oncology therapeutics based on its propriet
Read more →PHIORXi Pharmaceuticals Reports First Quarter 2018 Financial Results and Recent Corporate Highlights Reduced cash burn per quarter by 20% from $2.5 million to $2 million Expect to expand external collaborations in the coming
RXi Pharmaceuticals Reports First Quarter 2018 Financial Results and Recent Corporate Highlights Reduced cash burn per quarter by 20% from $2.5 million to $2 million Expect to expand external collaborations in the coming months in IO and ACT Publication in Molecular Therapy o
Read more →PHIOForward Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "believes," "anticipates," "plans," "expects," "i
RXi Pharmaceuticals NASDAQ: RXII Dr. Geert Cauwenbergh, Dr. Med. Sc. President and CEO www.rxipharma.com Developing the Next Generation of Immuno-Oncology Therapeutics Exhibit 99.1 Forward Looking Statements This presentation contains forward-looking statements within the mean
Read more →PHIORXi Pharmaceuticals Reports Fourth Quarter and Year End 2017 Financial Results and Recent Corporate Highlights
RXi Pharmaceuticals Reports Fourth Quarter and Year End 2017 Financial Results and Recent Corporate Highlights MARLBOROUGH, Mass., March 26, 2018 /PRNewswire/ RXi Pharmaceuticals Corporation (NASDAQ: RXII) a biotechnology company developing immuno-oncology therapeutics based o
Read more →PHIORXi Pharmaceuticals Announces Reverse Stock Split
RXi Pharmaceuticals Announces Reverse Stock Split MARLBOROUGH, Mass., January 5, 2018 /PRNewswire/ RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage company developing a new class of RNAi-based therapeutics, today announced a reverse stock split of its shares of
Read more →PHIORXi Pharmaceuticals Reports Third Quarter 2017 Financial Results and Recent Corporate Highlights
RXi Pharmaceuticals Reports Third Quarter 2017 Financial Results and Recent Corporate Highlights MARLBOROUGH, Mass., November 8, 2017 /PRNewswire/ RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics that address signi
Read more →PHIORXi Pharmaceuticals Reports Second Quarter 2017 Financial Results and Recent Corporate Highlights
RXi Pharmaceuticals Reports Second Quarter 2017 Financial Results and Recent Corporate Highlights MARLBOROUGH, Mass., August 10, 2017 /PRNewswire/ RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics that address signi
Read more →PHIORXi Pharmaceuticals Reports First Quarter 2017 Financial Results and Recent Corporate Highlights
RXi Pharmaceuticals Reports First Quarter 2017 Financial Results and Recent Corporate Highlights MARLBOROUGH, Mass., May 11, 2017 /PRNewswire/ RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics that address significa
Read more →PHIORXi Pharmaceuticals Topical Application of Self-delivering RNAi (sd-rxRNA ) Compounds for Reduction of Hyperpigmentation Melissa Maxwell, Katherine Holton, James Cardia, Richard Looby, Michael Byrne, Karen Bulock SOCIETY
Topical Application of Self-delivering RNAi (sd-rxRNA ) Compounds for Reduction of Hyperpigmentation Melissa Maxwell, Katherine Holton, James Cardia, Richard Looby, Michael Byrne, Karen Bulock SOCIETY FOR INVESTIGATIVE DERMATOLOGY Foundations for Future Discovery RXi Pharma
Read more →PHIORXi Pharmaceuticals Reports Fourth Quarter and Year End 2016 Financial Results and Recent Corporate Highlights
RXi Pharmaceuticals Reports Fourth Quarter and Year End 2016 Financial Results and Recent Corporate MARLBOROUGH, Mass., March 30, 2017 /PRNewswire/ RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics that address sign
Read more →PHIORXi Pharmaceuticals Announces Closing of $11.5 Million Underwritten Public Offering and Full Exercise of Over-allotment Option
RXi Pharmaceuticals Announces Closing of $11.5 Million Underwritten Public Offering and Full Exercise of Over-allotment Option MARLBOROUGH, Mass., December 21, 2016/PRNewswire/ RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage company developing innovative thera
Read more →PHIORXi Pharmaceuticals Announces Pricing of $10 Million Underwritten Public Offering
RXi Pharmaceuticals Announces Pricing of $10 Million Underwritten Public Offering Mass., December 16, 2016/PRNewswire/ RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage company developing innovative therapeutics that address significant unmet medical needs, today
Read more →PHIORXi Pharmaceuticals Reports Third Quarter 2016 Financial Results and Highlights Recent Corporate Developments
RXi Pharmaceuticals Reports Third Quarter 2016 Financial Results and Highlights Recent Corporate Developments MARLBOROUGH, Mass., November 10, 2016 /PRNewswire/ RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage company developing innovative therapeutics that add
Read more →PHIORXi Pharmaceuticals Reports Second Quarter 2016 Financial Results and Highlights Recent Corporate Developments
RXi Pharmaceuticals Reports Second Quarter 2016 Financial Results and Highlights Recent Corporate MARLBOROUGH, Mass., August 11, 2016 /PRNewswire/ RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics that address signi
Read more →PHIORXi Pharmaceuticals Reports First Quarter 2016 Financial Results and Highlights Recent Corporate Developments
RXi Pharmaceuticals Reports First Quarter 2016 Financial Results and Highlights Recent Corporate Developments MARLBOROUGH, Mass., May 12, 2016 /PRNewswire/ RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics in derma
Read more →PHIORXi Pharmaceuticals Reports Fourth Quarter and Year End 2015 Financial Results and Recent Corporate Highlights
RXi Pharmaceuticals Reports Fourth Quarter and Year End 2015 Financial Results and Recent Corporate Highlights MARLBOROUGH, Mass., March 30, 2016 /PRNewswire/ RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics in de
Read more →PHIOProperty of RXi Pharmaceuticals Forward Looking Statements Forward Looking Statements This presentation contains forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Word
Potential indications include c utaneous hyperpigmentation disorders, lentigines (age spots, liver spots, freckles) Acquired estate provides multiple development opportunities OPKO RNAi Assets N ovel potent sd rxRNA compounds targeting VEGF for potential intra ocular therapy for
Read more →PHIORXi Pharmaceuticals Reports Financial Results for the First Quarter of 2014
RXi Pharmaceuticals Reports Financial Results for the First Quarter of 2014 MARLBOROUGH, Mass., May 14, 2014 /PRNewswire/ RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies address
Read more →PHIORXi Pharmaceuticals Reports Full Year 2013 Financial Results
RXi Pharmaceuticals Reports Full Year 2013 Financial Results WESTBOROUGH, Mass., March 28, 2014 /PRNewswire/ RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unm
Read more →PHIORXi Pharmaceuticals Reports Financial Results for the Third Quarter of 2013 WESTBOROUGH, MA
RXi Pharmaceuticals Reports Financial Results for the Third Quarter of 2013 WESTBOROUGH, MA November 14, 2013 RXi Pharmaceuticals Corporation (OTCQX: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unm
Read more →PHIORXi Pharmaceuticals Reports Financial Results for the Second Quarter of 2013 WESTBOROUGH, MA
RXi Pharmaceuticals Reports Financial Results for the Second Quarter of 2013 WESTBOROUGH, MA August 14, 2013 RXi Pharmaceuticals Corporation (OTCQX: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unme
Read more →PHIORXi Pharmaceuticals Announces Application for NASDAQ Capital Market Listing and Reverse Stock Split Westborough, MA
RXi Pharmaceuticals Announces Application for NASDAQ Capital Market Listing and Reverse Stock Split Westborough, MA July 22, 2013 - (PR Newswire) - RXi Pharmaceuticals Corporation (OTCQX: RXII), a biotechnology company focused on discovering, developing and commercializing inno
Read more →PHIORXi Pharmaceuticals Reports Financial Results for the First Quarter of 2013 Acquired substantially all of OPKO Health, Inc. s siRNA assets in early 2013 Completed a private placement in March 2013 with gross proceeds of
RXi Pharmaceuticals Reports Financial Results for the First Quarter of 2013 Acquired substantially all of OPKO Health, Inc. s siRNA assets in early 2013 Completed a private placement in March 2013 with gross proceeds of $16.4 million, led by OPKO Health, Inc. and Frost Gamma I
Read more →PHIORXi Pharmaceuticals Reports Full Year 2012 Financial Results Cash burn of approximately $4.6 million for fiscal 2012 and $5.1 million in remaining cash at year-end Spin-off completed and filed IND for RXI-109; started tw
RXi Pharmaceuticals Reports Full Year 2012 Financial Results Cash burn of approximately $4.6 million for fiscal 2012 and $5.1 million in remaining cash at year-end Spin-off completed and filed IND for RXI-109; started two Phase 1 studies and completed dosing in those studies
Read more →PHIORXi Pharmaceuticals Corporation March 2013 OTC: RXII Next Generation in RNAi Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform
RXi Pharmaceuticals Corporation March 2013 OTC: RXII Next Generation in RNAi Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as believes, anticipates, plans,
Read more →PHIORXi Pharmaceuticals Reports Financial Results for the Third Quarter of 2012 Appointment of Jeannette Graf, M.D. and Leroy Young, M.D., and re-appointment of Craig Mello, Ph.D., Nobel Laureate for the discovery of the RNA
RXi Pharmaceuticals Reports Financial Results for the Third Quarter of 2012 Westborough, MA, November 14, 2012 RXi Pharmaceuticals Corporation (OTC: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unme
Read more →PHIORXi Pharmaceuticals Receives FDA Clearance to Begin Clinical Trial with RXI-109 First study to evaluate tolerance and potential surrogate parameters for scar reduction WORCESTER, Mass. - (BUSINESS WIRE) - RXi Pharmaceuti
RXi Pharmaceuticals Receives FDA Clearance to Begin Clinical Trial with RXI-109 First study to evaluate tolerance and potential surrogate parameters for scar reduction WORCESTER, Mass. - (BUSINESS WIRE) - RXi Pharmaceuticals Corporation (OTCBB: RXII.OB) today announced that it
Read more →Competitive Position
How PHIO ranks across every disease it competes inCompetitive Position is a premium feature
See how PHIO ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial